Innovative vaccine targets streptococci

Posey, L. Michael
November 2005
Pharmacy Today;Nov2005, Vol. 11 Issue 11, p10
The article reports on a study that focuses on the safety and immunogenicity of a 26-valent vaccine developed by ID Biomedical Corp. The study was published in the October 15 issue of "Clinical Infectious Diseases." Strep throat is a common childhood infection caused by group A streptococcus (GAS). The filamentous M protein is a coiled-coil dimer on the surface of GAS. It occurs in more than 100 immunological distinct types. It was noted that advances in molecular techniques have allowed researchers to identify a portion of the M proteins called an epitope that confers microbial immunity and to figure out which epitopes on M protein produce harmful cross-reactive antibodies. The tested vaccine includes the beneficial epitopes from 26 different GAS serotypes that cause between 85% and 90% of the acute pharyngitis and serious invasive GAS cases.


Related Articles

  • EXPANDED HUMAN TESTING OF NASAL FLU VACCINE BEGINS.  // Worldwide Biotech;Jul2001, Vol. 13 Issue 7, p2 

    Announces the start of the expanded human safety and immunogenecity testing of the intranasal influenza vaccine from ID Biomedical Corporation.

  • Self Heat-Shock Protein (hsp60) Peptide Serves in a Conjugate Vaccine against a Lethal... Konen-Waisman, Stephanie; Cohen, Avi; Fridkin, Mati; Cohen, Irun R. // Journal of Infectious Diseases;2/1/99, Vol. 179 Issue 2, p403 

    Examines the role of self heat-shock protein (hsp60) peptide in a conjugate vaccine against Streptococcal pneumoniae infection. Assistance to T cells provided by hsp60 for a response to T independent capsular polysaccharides; Resistance induced by the vaccine.

  • Pneumococcal vaccine. Joon Young Song; Hee Jin Cheong // Journal of the Korean Medical Association / Taehan Uisa Hyophoe ;Sep2014, Vol. 57 Issue 9, p780 

    Streptococcus pneumoniae (pneumococcus) is an important pathogen with high morbidity and mortality worldwide. Pneumococcal vaccine is an important measure to reduce the pneumococcal disease burden. Currently, two pneumococcal vaccines are available in adults, including 23-valent pneumococcal...

  • Canadian company to develop mock pandemic vaccine. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;3/1/2005, Vol. 172 Issue 5, p623 

    Focuses on a mock pandemic vaccine being developed by Vancouver-based ID Biomedical Corp. to protect people against H5N1 influenza in British Columbia. Utilization of reverse genetics technology; Requirements for the phase II clinical trials; Comment from Michele Roy, spokesperson for ID...

  • Role of M Protein in Adherence of Group A Streptococci.  // JAMA: Journal of the American Medical Association;10/9/91, Vol. 266 Issue 14, p1919 

    Presents an abstract of the article 'Role of M Protein in Adherence of Group A Streptococci,' by Michael G. Caparon et al, published in a 1991 issue of the 'Journal of Infection and Immunity.'

  • Immunogenicity of a divalent group A streptococcal vaccine. Ding, Yuexia; Ni, Qiongqiong; Liu, Jinlai; Yu, Buyun // Rheumatology International;Apr2013, Vol. 33 Issue 4, p1013 

    We designed and recombined the polypeptide based on the M protein of group A streptococci (GAS)-the causative pathogen of rheumatic fever and rheumatic heart disease, which would be a divalent vaccine to prevent and defend the diseases in relation to the different GAS strains. A divalent vaccine...

  • FDA safety alert on GBS antigen screening.  // American Family Physician;7/1/1997, Vol. 56 Issue 1, p284 

    Offers a look at the guidelines for the use of test kits to detect the group B streptococcal (GBS) antigen as issued by the United States Food and Drug Adminstration. GBS antigen test use in maternity patients and infants.

  • Knowledge of serotype prevalence & burden of invasive pneumococcal disease: a prerequisite to vaccine introduction in the country. Kanungo, Reba // Indian Journal of Medical Research;Sep2015, Vol. 142 Issue 3, p241 

    The author comments on a study by V. Balaji and colleagues which examined the burden of invasive pneumococcal disease (IPD) and serotype prevalence in India in relation to the introduction of a pneumococcal vaccine. Topics discussed include the coverage of pneumococcal conjugate vaccine-10...

  • Invasive Pneumococcal Disease in Young Children Before Licensure of 13-Valent Pneumococcal Conjugate Vaccine -- United States, 2007.  // MMWR: Morbidity & Mortality Weekly Report;3/12/2010, Vol. 59 Issue 9, p253 

    The article reports on cases of invasive pneumococcal disease (IPD) in young children in the U.S. in 2007 before approval of 13-valent pneumococcal conjugate vaccine. It is noted that the disease caused by Streptococcus pneumoniae remains the top cause of serious illness among adults and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics